Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Veklury (remdesivir by Year
Veklury (remdesivir — COVID-19 antiviral) — U.S. sales ($M) ($M)
Gilead Sciences Veklury (remdesivir: $470M in FY2025, down 47.3% from a year earlier.
Latest, FY2025
470
Period ended Dec 31, 2025
Change on a year earlier
-47.3%
892 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Veklury (remdesivir — COVID-19 antiviral) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 470 | -47.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 892 | -8.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 972 | -38.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,575 | -56.7% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 3,640 | +79.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 2,026 | – | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Veklury (remdesivir ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/veklury-total-us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.